Stress Management Intervention for Living With Epilepsy (SMILE)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

95 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2015-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study will examine whether a stress reduction intervention reduces the number of seizures in people with drug resistant epilepsy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Stimulation of Sleep in Patients With Epilepsy

NCT04716673

Epilepsy

RECRUITING NA

Creating a Healthy L.I.F.E: Lifestyle Interventions For Epilepsy

NCT05283200

Lifestyle

ACTIVE_NOT_RECRUITING NA

External Trigeminal Nerve Stimulation for Drug Resistent Epilepsy

NCT01978470

Seizure Disorder

UNKNOWN NA

Electrophysiologic Studies of Cognition in Epilepsy Patients

NCT05769634

Drug-resistant Epilepsy

COMPLETED NA

A Study of IBRF Disorders of Consciousness Advanced Care/MultiModal Care Protocol in Severe Disorders of Consciousness

NCT02696512

Brain Injury

UNKNOWN PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will examine whether a stress reduction intervention reduces the number of seizures in people with drug resistant epilepsy. In the proposed randomized controlled, double blind trial, the investigators will enroll subjects with frequent seizures, especially those who identify stress as a seizure precipitant. There is an observational phase (8-12 weeks) and a treatment phase (12 weeks). During the observational phase, subjects will be monitored multiple times daily via smart phone devices, in order to identify high risk days for seizures. In the treatment phase, subjects will be randomly assigned to one of two groups receiving different focused attention practices. These behavioral interventions will be administered daily with extra interventions applied on days of higher risk.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Epilepsy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Progressive muscle relaxation

Subjects practice a progressive muscle relaxation exercise for 15 minutes every AM and 5 minutes every PM

Group Type ACTIVE_COMPARATOR

Progressive muscle relaxation

Intervention Type BEHAVIORAL

Subjects practice a progressive muscle relaxation exercise for 15 minutes every AM and 5 minutes every PM

Both groups will practice twice daily, one 15 minute practice in the AM and a 5 minute practice in the PM. An additional 5 minute mid-day practice will occur only when e-diary entries from experience sampling meet specific predetermined criteria.

Sham exercise

Subjects practice a sham exercise consisting of focused attention activities

Group Type SHAM_COMPARATOR

Sham exercise

Intervention Type BEHAVIORAL

The focused attention practices will consist of one or more of the following components: movement of body parts, breathing exercises, and writing exercises.

Both groups will practice twice daily, one 15 minute practice in the AM and a 5 minute practice in the PM. An additional 5 minute mid-day practice will occur only when e-diary entries from experience sampling meet specific predetermined criteria.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Progressive muscle relaxation

Subjects practice a progressive muscle relaxation exercise for 15 minutes every AM and 5 minutes every PM

Both groups will practice twice daily, one 15 minute practice in the AM and a 5 minute practice in the PM. An additional 5 minute mid-day practice will occur only when e-diary entries from experience sampling meet specific predetermined criteria.

Intervention Type BEHAVIORAL

Sham exercise

The focused attention practices will consist of one or more of the following components: movement of body parts, breathing exercises, and writing exercises.

Both groups will practice twice daily, one 15 minute practice in the AM and a 5 minute practice in the PM. An additional 5 minute mid-day practice will occur only when e-diary entries from experience sampling meet specific predetermined criteria.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 years and above
* English speaking
* Partial epilepsy consistent with ILAE criteria supported by either EEG or MRI data
* Experiencing at least 2 seizures/month
* Reported awareness of all seizures, including seizures in a cluster
* One of the following:

1. Patient-reported ability to self-predict seizures
2. Patient-reported awareness of trigger factors, including stress
3. Patient-reported awareness of premonitory features
* Able to maintain accurate e-diary independently
* Minimum 6th grade reading level as screened by WRAT administration
* Must be on a stable dose of anti-epileptic drugs for at least 30 days prior to study entry
* May be on stable dose of SSRI, SNRI, or atypical antipsychotic for at least 6 months
* May be on a stable dose of benzodiazepines (if so, dose stable for at least 30 days prior to study entry)

For inclusion in clinical trial phase, patient must be/have:

* A minimum of 4 seizures documented in the 8-week baseline phase (or 6 seizures in the 12-week extended baseline phase)
* At least 1 seizure per 4-week period in two of the three 4-week periods in the extended baseline phase
* Diaries satisfactorily completed during baseline phase
* Complied with study requirements during the baseline phase

Exclusion Criteria

* Non-motor simple partial seizures only
* Concurrent VNS use
* History of suicide attempt within the past 2 years
* Current suicidality
* Not competent to sign consent
* Status epilepticus within the previous 6 months
* Began regularly using behavioral techniques for stress reduction within past 3 months
* Did not benefit from an adequate trial of a valid stress reduction technique
* Progressive neurologic condition that the investigator believes would affect seizure frequency
* Any history of substance abuse within the previous 2 years
* History of poor medication compliance as judged by the investigator
* Psychiatric illness that requires change in medication dose
* Any medical or psychiatric condition that would impair reliable participation in the trial
* Intermittent use of benzodiazepines (if used for sleep, will be determined case by case)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No